At AHA 2021, some major clinical trials broke new ground with familiar agents while others validated management approaches previously informed largely by clinical experience. Here’s my take.
Here are my thoughts on the exciting studies of novel therapies in heart failure, including a myosin inhibitor, statin use, and electrical cardioversion for atrial fibrillation.
At AHA 2021, new data on the use of telehealth platforms demonstrated that video visits are a feasible approach to managing patients with heart failure.
*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.